193 related articles for article (PubMed ID: 29389973)
21. Tamoxifen, flaxseed, and the lignan enterolactone increase stroma- and cancer cell-derived IL-1Ra and decrease tumor angiogenesis in estrogen-dependent breast cancer.
Lindahl G; Saarinen N; Abrahamsson A; Dabrosin C
Cancer Res; 2011 Jan; 71(1):51-60. PubMed ID: 21097717
[TBL] [Abstract][Full Text] [Related]
22. Obesity and the associated mediators leptin, estrogen and IGF-I enhance the cell proliferation and early tumorigenesis of breast cancer cells.
Lautenbach A; Budde A; Wrann CD; Teichmann B; Vieten G; Karl T; Nave H
Nutr Cancer; 2009; 61(4):484-91. PubMed ID: 19838920
[TBL] [Abstract][Full Text] [Related]
23. Lunasin Attenuates Obesity-Associated Metastasis of 4T1 Breast Cancer Cell through Anti-Inflammatory Property.
Hsieh CC; Wang CH; Huang YS
Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27983683
[TBL] [Abstract][Full Text] [Related]
24. Formulation of Anti-miR-21 and 4-Hydroxytamoxifen Co-loaded Biodegradable Polymer Nanoparticles and Their Antiproliferative Effect on Breast Cancer Cells.
Devulapally R; Sekar TV; Paulmurugan R
Mol Pharm; 2015 Jun; 12(6):2080-92. PubMed ID: 25880495
[TBL] [Abstract][Full Text] [Related]
25. Dietary flaxseed oil reduces adipocyte size, adipose monocyte chemoattractant protein-1 levels and T-cell infiltration in obese, insulin-resistant rats.
Baranowski M; Enns J; Blewett H; Yakandawala U; Zahradka P; Taylor CG
Cytokine; 2012 Aug; 59(2):382-91. PubMed ID: 22592037
[TBL] [Abstract][Full Text] [Related]
26. Leptin, adipocytes and breast cancer: Focus on inflammation and anti-tumor immunity.
Delort L; Rossary A; Farges MC; Vasson MP; Caldefie-Chézet F
Life Sci; 2015 Nov; 140():37-48. PubMed ID: 25957709
[TBL] [Abstract][Full Text] [Related]
27. Tamoxifen selects for breast cancer cells with mammosphere forming capacity and increased growth rate.
Raffo D; Berardi DE; Pontiggia O; Todaro L; de Kier Joffé EB; Simian M
Breast Cancer Res Treat; 2013 Dec; 142(3):537-48. PubMed ID: 24258256
[TBL] [Abstract][Full Text] [Related]
28. Adipokine expression profile in adipocytes of different mouse models of obesity.
Boucher J; Castan-Laurell I; Daviaud D; Guigné C; Buléon M; Carpéné C; Saulnier-Blache JS; Valet P
Horm Metab Res; 2005 Dec; 37(12):761-7. PubMed ID: 16372231
[TBL] [Abstract][Full Text] [Related]
29. Mitochondrial "power" drives tamoxifen resistance: NQO1 and GCLC are new therapeutic targets in breast cancer.
Fiorillo M; Sotgia F; Sisci D; Cappello AR; Lisanti MP
Oncotarget; 2017 Mar; 8(12):20309-20327. PubMed ID: 28411284
[TBL] [Abstract][Full Text] [Related]
30. Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells.
Berstein LM; Yue W; Wang JP; Santen RJ
Breast Cancer Res Treat; 2011 Jul; 128(1):109-17. PubMed ID: 20683653
[TBL] [Abstract][Full Text] [Related]
31. A risk-associated Active transcriptome phenotype expressed by histologically normal human breast tissue and linked to a pro-tumorigenic adipocyte population.
Kang T; Yau C; Wong CK; Sanborn JZ; Newton Y; Vaske C; Benz SC; Krings G; Camarda R; Henry JE; Stuart J; Powell M; Benz CC
Breast Cancer Res; 2020 Jul; 22(1):81. PubMed ID: 32736587
[TBL] [Abstract][Full Text] [Related]
32. Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance.
Busch S; Sims AH; Stål O; Fernö M; Landberg G
Cancer Res; 2015 Apr; 75(7):1457-69. PubMed ID: 25833830
[TBL] [Abstract][Full Text] [Related]
33. In vivo and in vitro demonstration of herb-drug interference in human breast cancer cells treated with tamoxifen and trastuzumab.
Chen JL; Wang JY; Tsai YF; Lin YH; Tseng LM; Chang WC; King KL; Chen WS; Chiu JH; Shyr YM
Menopause; 2013 Jun; 20(6):646-54. PubMed ID: 23340260
[TBL] [Abstract][Full Text] [Related]
34. A novel chemical, STF-083010, reverses tamoxifen-related drug resistance in breast cancer by inhibiting IRE1/XBP1.
Ming J; Ruan S; Wang M; Ye D; Fan N; Meng Q; Tian B; Huang T
Oncotarget; 2015 Dec; 6(38):40692-703. PubMed ID: 26517687
[TBL] [Abstract][Full Text] [Related]
35. A naringenin-tamoxifen combination impairs cell proliferation and survival of MCF-7 breast cancer cells.
Hatkevich T; Ramos J; Santos-Sanchez I; Patel YM
Exp Cell Res; 2014 Oct; 327(2):331-9. PubMed ID: 24881818
[TBL] [Abstract][Full Text] [Related]
36. Effect of tamoxifen and fulvestrant long-term treatments on ROS production and (pro/anti)-oxidant enzymes mRNA levels in a MCF-7-derived breast cancer cell line.
Badia E; Morena M; Lauret C; Boulahtouf A; Boulle N; Cavaillès V; Balaguer P; Cristol JP
Breast Cancer; 2016 Sep; 23(5):692-700. PubMed ID: 26193841
[TBL] [Abstract][Full Text] [Related]
37. Cyclooxygenase-2 utilizes Jun N-terminal kinases to induce invasion, but not tamoxifen resistance, in MCF-7 breast cancer cells.
Gonzalez-Villasana V; Gutiérrez-Puente Y; Tari AM
Oncol Rep; 2013 Sep; 30(3):1506-10. PubMed ID: 23783392
[TBL] [Abstract][Full Text] [Related]
38. Benefits of complete polyamine deprivation in hormone responsive and hormone resistant MCF-7 human breast adenocarcinoma in vivo.
Leveque J; Foucher F; Havouis R; Desury D; Grall JY; Moulinoux JP
Anticancer Res; 2000; 20(1A):97-101. PubMed ID: 10769640
[TBL] [Abstract][Full Text] [Related]
39. Differential response to phytoestrogens in endocrine sensitive and resistant breast cancer cells in vitro.
Limer JL; Parkes AT; Speirs V
Int J Cancer; 2006 Aug; 119(3):515-21. PubMed ID: 16506217
[TBL] [Abstract][Full Text] [Related]
40. Antiestrogens are pro-apoptotic in normal human breast epithelial cells.
Somaï S; Chaouat M; Jacob D; Perrot JY; Rostène W; Forgez P; Gompel A
Int J Cancer; 2003 Jul; 105(5):607-12. PubMed ID: 12740907
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
